methyl N-[(4'-{[(4-ethyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino}-1,1'-biphenyl-4-yl)sulfonyl]-L-valinate | 857080-24-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl N-[(4'-{[(4-ethyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino}-1,1'-biphenyl-4-yl)sulfonyl]-L-valinate
• 英文别名: methyl (2S)-2-[[4-[4-[(4-ethyl-3-methyl-1-benzofuran-2-carbonyl)amino]phenyl]phenyl]sulfonylamino]-3-methylbutanoate
• CAS: 857080-24-1
• 化学式: C₃₀H₃₂N₂O₆S
• 分子量: 548.66
• InChiKey: PCRZLWXKQSUZHK-MHZLTWQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl N-[(4'-{[(4-ethyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino}-1,1'-biphenyl-4-yl)sulfonyl]-L-valinate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 18.0h， 生成 N-[(4'-{[(4-ethyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino}-1,1'-biphenyl-4-yl)sulfonyl]-L-valine
  参考文献：
  名称：

  3,4-Disubstituted benzofuran P1′ MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding

  摘要：

  Potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors have been prepared. Selectivity over MMP-2 was achieved through a substituent at the C4 position of the benzofuran P1' moiety of the molecule. By replacing a backbone benzene with a pyridine and valine with threonine, compounds (e. g., 44) with greatly reduced plasma protein binding were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.008
• 作为产物：
  描述：

  3-methyl-4-ethylbenzofuran-2-carboxylic acid 、 (S)-2-(4'-aminobiphenyl-4-sulfonylamino)-3-methylbutyric acid methyl ester 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 methyl N-[(4'-{[(4-ethyl-3-methyl-1-benzofuran-2-yl)carbonyl]amino}-1,1'-biphenyl-4-yl)sulfonyl]-L-valinate
  参考文献：
  名称：

  3,4-Disubstituted benzofuran P1′ MMP-13 inhibitors: Optimization of selectivity and reduction of protein binding

  摘要：

  Potent 3,4-disubstituted benzofuran P1' MMP-13 inhibitors have been prepared. Selectivity over MMP-2 was achieved through a substituent at the C4 position of the benzofuran P1' moiety of the molecule. By replacing a backbone benzene with a pyridine and valine with threonine, compounds (e. g., 44) with greatly reduced plasma protein binding were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.008

文献信息

• Biaryl sulfonamides and methods for using same
  申请人：Levin Ian Jeremy

  公开号：US20050143422A1

  公开（公告）日：2005-06-30

  The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.

  本发明涉及联苯磺酰胺及其用途，例如作为金属蛋白酶抑制剂。
• [EN] BIARYL SULFONAMIDES AS MMP INHIBITORS<br/>[FR] SULFONAMIDES BIARYLIQUES INHIBITEURS DE MMP
  申请人：WYETH CORP

  公开号：WO2005061477A1

  公开（公告）日：2005-07-07

  The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors: Formule (I).

  本发明涉及联苯磺酰胺及其用途，例如，作为金属蛋白酶抑制剂：式（I）。
• Biaryl Sulfonamides and Methods for Using Same
  申请人：Levin Jeremy Ian

  公开号：US20100137298A1

  公开（公告）日：2010-06-03

  The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.

  本发明涉及双芳基磺酰胺及其用途，例如作为金属蛋白酶抑制剂。
• BIARYL SULFONAMIDES AS MMP INHIBITORS
  申请人：Wyeth

  公开号：EP1692124A1

  公开（公告）日：2006-08-23
• US7420001B2
  申请人：——

  公开号：US7420001B2

  公开（公告）日：2008-09-02